Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06629129
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-28
Brief Title:
Effect of Latanoprost on Optic Nerve Perfusion
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Optic Nerve Head Perfusion Following Treatment with Latanoprost 0005 in Primary Open Angle Glaucoma an Optical Coherence Tomography Angiography Study
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
46 eyes of 23 patients have been treated with topical Latanoprost 0005 visual field was performed on all eyes NFLT was measured using OCT Radial peripapillary capillary RPC vascular density was measured using OCTA mean ocular perfusion pressure MOPP and RPC vascular density were measured before and after treatment BY 2-3 MONTHS
Detailed Description:
All patients had bilateral primary open angle glaucoma diagnosed by increased IOP visual field changes and defective nerve fiber layer thickness NFLT on OCT examination
All patients treated with topical Latanoprost 0005 XalatanTM 25 ml eye drops Pfizer Inclusion criteria age gt 20 years newly diagnosed patients with POAG The exclusion criteria included optic nerve lesions other than glaucomatous changes All patients completed their ophthalmic examination to detect BCVA cycloplegic refraction and anterior segment examination IOP measuring by applanation tonometer and indirect ophthalmoscope fundus examination
Visual field testing The thickness of NFL around the disc was evaluated using spectral domain optical coherence tomography OCT Optovue octa was used to quantify the density of the radial peripapillary capillary RPC vessels This study employed software to quantify the capillary microvasculature density in both the entire image and in the peripapillary region specifically the superior nasal inferior and temporal quadrants
The mean arterial blood pressure MAP was determined by adding the diastolic blood pressure DBP to one third of the difference between systolic blood pressure and the diastolic blood pressure
All eyes were treated with topical latanoprost 0005 XalatanTM 25 ml eye drops Pfizer with dose of one drop at bedtime IOP MOPP NFLT and RPC vascular density were measured before the beginning of treatment and 1 and 3 months after treatment
All patients treated with topical Latanoprost 0005 XalatanTM 25 ml eye drops Pfizer Inclusion criteria age gt 20 years newly diagnosed patients with POAG The exclusion criteria included optic nerve lesions other than glaucomatous changes All patients completed their ophthalmic examination to detect BCVA cycloplegic refraction and anterior segment examination IOP measuring by applanation tonometer and indirect ophthalmoscope fundus examination
Visual field testing The thickness of NFL around the disc was evaluated using spectral domain optical coherence tomography OCT Optovue octa was used to quantify the density of the radial peripapillary capillary RPC vessels This study employed software to quantify the capillary microvasculature density in both the entire image and in the peripapillary region specifically the superior nasal inferior and temporal quadrants
The mean arterial blood pressure MAP was determined by adding the diastolic blood pressure DBP to one third of the difference between systolic blood pressure and the diastolic blood pressure
All eyes were treated with topical latanoprost 0005 XalatanTM 25 ml eye drops Pfizer with dose of one drop at bedtime IOP MOPP NFLT and RPC vascular density were measured before the beginning of treatment and 1 and 3 months after treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None